Blar i forfatter Det helsevitenskapelige fakultet "Holm, Kristian"

Viser treff 1-3 av 3

    • Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19 

      Trøseid, Marius; Holter, Jan Cato; Holm, Kristian; Vestad, Beate; Sazonova, Taisiia; Granerud, Beathe Kiland; Dyrhol-Riise, Anne Ma; Holten, Aleksander Rygh; Tonby, Kristian; Kildal, Anders Benjamin; Heggelund, Lars; Tveita, Anders Aune; Bøe, Simen; Müller, Karl Erik; Jenum, Synne; Hov, Johannes Espolin Roksund; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-02-23)
      Background - Gut microbiota alterations have been reported in hospitalized COVID-19 patients, with reduced alpha diversity and altered microbiota composition related to respiratory failure. However, data regarding gut microbiota and mortality are scarce.<p> <p>Methods - Rectal swabs for gut microbiota analyses were collected within 48 h after hospital admission (baseline; n = 123) and three-month ...

    • Intestinal fatty acid binding protein is associated with cardiac function and gut dysbiosis in chronic heart failure 

      Nendl, Andraz; Raju, Sajan; Broch, Kaspar; Mayerhofer, Christiane Caroline; Holm, Kristian; Halvorsen, Bente; Lappegård, Knut Tore; Moscavitch, Samuel; Hov, Johannes Espolin Roksund; Seljeflot, Ingebjørg; Trøseid, Marius; Awoyemi, Ayodeji Olawale (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-02)
      Background: The gut microbiota in patients with chronic heart failure (HF) is characterized by low bacterial diversity and reduced ability to synthesize beneficial metabolites. These changes may facilitate leakage of whole bacteria or bacterial products from the gut into the bloodstream, which may activate the innate immune system and contribute to the low-grade inflammation seen in HF. In this ...

    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-28)
      Background - The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).<p> <p>Methods - In a multicentre, prospective randomized open label, blinded ...